Exercise: Can There Be Too Much Of A Good Thing?

In recent years researchers have developed a more complicated view of the relationship of health and exercise. Although observational studies have consistently shown that some physical activity is better than none, studies that have drilled deeper into the data suggest that these health benefits may be curtailed in people who exercise very frequently or very intensely. Now two new studies from …

Kristin Chenoweth Knows Her Count — Do You?

Kristin Chenoweth Knows Her Count -- Do You?While the recent announcement from the Roundabout Theater Company that Tony Award winner Kristin Chenoweth will return to Broadway in February in On the 20th Century, a 1978 musical comedy set aboard a luxury train traveling from Chicago to New York City, is welcomed news, it certainly is no surprise. But recently, over a steaming cup of coffee the 5-foot nothing firecracker talked to me about her battle to breathe easy (literally) when she announced publicly that she had been living with chronic asthma for over a decade. Photo Credit: John Russo I see no need to hide the fact

Gluten-Free Diet Reduces Risk Of Type 1 Diabetes In Mice

Gluten-Free Diet Reduces Risk Of Type 1 Diabetes In MiceBy: Rachael Rettner, Senior Writer Published: 05/15/2014 09:01 AM EDT on LiveScience Exposure to a gluten-free diet prenatally or very early in life — in the womb or through a mother's milk — may reduce the risk of type 1 diabetes, at least in mice, a new study suggests. In the study, researchers used a type of mouse that is prone to developing type 1 diabetes. Mouse mothers were fed either a gluten-free diet or a regular diet during pregnancy and the time when they were nursing. When the mouse pups were four weeks old, the researchers transitioned them to

U.S. veterans Affairs chief Shinseki vows timely action on care delays

By David Lawder WASHINGTON (Reuters) – U.S. Veterans Affairs Secretary Eric Shinseki said on Thursday he would take \”timely action\” to deal with allegations that veterans died while waiting for medical care at VA facilities in Phoenix while officials masked months-long waiting time for appointments. Shinseki, in written testimony to the Senate Veterans Affairs Committee, said he was \”personally angered and saddened\” by the allegations, but it was important for the agency’s Office of the Inspector General (OIG) to conduct a thorough review. \”If these allegations are true, they are completely unacceptable – to veterans, to me and to our dedicated VHA (Veterans Health Administration) employees. If they are substantiated by OIG, responsible timely action will be taken.\” Shinseki’s appearance before the committee is his first major public appearance to address the scandal over long wait times at VA medical facilities around the country.

U.S. court dismisses Teva case to block copies of Copaxone

A U.S. district court dismissed a case by Teva Pharmaceutical Industries Ltd against the U.S. Food and Drug Administration, part of the Israeli company’s broad legal battle aimed at stopping generic versions of its Copaxone drug for multiple sclerosis. The case, in U.S. District Court in Washington, D.C., was dismissed on Wednesday as being premature because the FDA had not yet approved or rejected the applications for generic forms of the drug, Teva said. \”We are pleased that the judge has requested 24-hour notification of final action from FDA as to the (new drug applications) and continue to evaluate our options,\” Teva spokeswoman Denise Bradley said in a statement.

Eli Lilly loses UK Alimta patent case to Actavis

Eli Lilly and Co LLY.N said on Thursday it lost a patent case in the English High Court over its blockbuster Alimta lung cancer drug to generic drugmaker Actavis Plc ACT.N. The court ruled that Actavis would not infringe patents held by Lilly if it marketed certain alternative salt forms of the drug, known generically as pemetrexed, in Britain and several other European countries in 2015. Actavis wants to sell its alternative versions of the medicine when Alimta’s compound patents expire in 2015. \”Although Alimta’s compound patents remain in force and are expected to provide exclusivity in major European countries through 2015, we continue to believe that Alimta’s vitamin dosage regimen patents would be infringed by the entry of generic pemetrexed in Europe prior to June, 2021,\” Lilly’s general counsel Michael Harrington said in a statement.

1 56 57 58 59 60 109